

Using the Morbidity and Mortality Conference Model to Explore and Improve Community-Based Oncology Care

QUESTIONS (PLEASE CIRCLE ANSWER):

1. The Phase III KEYNOTE-024 study demonstrated a significant improvement in outcomes with pembrolizumab compared to platinum-based chemotherapy as first-line therapy for patients with advanced NSCLC and a PD-L1 tumor proportion score of _____ or greater.
 - a. 10%
 - b. 30%
 - c. 50%
2. Patients with early-stage NSCLC who are enrolled on the ALCHEMIST trial and who harbor neither EGFR nor ALK mutations will be randomly assigned to receive _____ or placebo.
 - a. Ipilimumab
 - b. Pembrolizumab
 - c. Nivolumab
3. Mutations in HER2, commonly involving insertions in exon 20, occur in approximately what proportion of patients with NSCLC?
 - a. 0.5%
 - b. 2%
 - c. 10%
4. For which patients with platinum-sensitive recurrent OC did niraparib maintenance therapy provide a significant progression-free survival benefit in comparison to placebo on the Phase III ENGOT-OV16/NOVA trial?
 - a. Patients with germline BRCA mutations
 - b. Patients without germline BRCA mutations
 - c. Patients with HRD positivity and no germline BRCA mutations
 - d. All of the above
 - e. Both a and b
 - f. Both b and c
5. The Phase III GOG-0218 trial demonstrated an improvement in _____ with the addition of bevacizumab to standard chemotherapy for patients with newly diagnosed, advanced OC.
 - a. Progression-free survival
 - b. Overall survival
 - c. Both a and b
6. Talimogene laherparepvec _____.
 - a. Is an attenuated oncolytic virus
 - b. Encodes GM-CSF and stimulates the immune response
 - c. Is effective only at the site of injection
 - d. All of the above
 - e. Both a and b
7. Patients with mCRC who have left-sided tumors have poorer outcomes with anti-EGFR antibodies than patients with right-sided tumors, regardless of KRAS status.
 - a. True
 - b. False
8. Studies investigating the efficacy of anti-PD-1 antibodies for advanced CRC have demonstrated _____ outcomes among patients with mismatch repair-deficient tumors than among those who have mismatch repair-proficient tumors.
 - a. Better
 - b. Worse
 - c. About the same
9. Current guidelines recommend that _____ undergo BRCA testing.
 - a. All patients with epithelial OC
 - b. Only patients with an Ashkenazi Jewish background
 - c. Only patients with a strong family history of breast cancer or OC at a young age
10. Mirvetuximab soravtansine (IMGN853) is _____.
 - a. An anti-angiogenic agent
 - b. An antibody-drug conjugate
 - c. A PARP inhibitor